Matches in Wikidata for { <http://www.wikidata.org/entity/Q104456250> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q104456250 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 4ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104456250 description "article scientifique publié en 2020" @default.
- Q104456250 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104456250 description "scientific article published on 04 December 2020" @default.
- Q104456250 description "wetenschappelijk artikel" @default.
- Q104456250 description "наукова стаття, опублікована 4 грудня 2020" @default.
- Q104456250 name "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 name "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 name "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 type Item @default.
- Q104456250 label "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 label "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 label "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 prefLabel "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 prefLabel "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 prefLabel "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 P1433 Q104456250-C2593801-43D1-4955-8A17-FE6409AF0647 @default.
- Q104456250 P1476 Q104456250-6F2300FD-58C0-4FA4-8BE8-61D597A2AE51 @default.
- Q104456250 P2093 Q104456250-0CFE06DF-E68D-417C-A715-CAF7EF80A7B7 @default.
- Q104456250 P2093 Q104456250-10BDFF20-F23D-403E-9C5A-61B5D9B34A2C @default.
- Q104456250 P2093 Q104456250-1EBA867C-EB02-4E98-9322-43B3D4058662 @default.
- Q104456250 P2093 Q104456250-3F41F05E-7C2F-49C5-9DCB-D4648C527213 @default.
- Q104456250 P2093 Q104456250-43A9DA84-FE95-48F1-A2CE-6331D0C208FF @default.
- Q104456250 P2093 Q104456250-4EFD6AD4-51DB-4A40-B212-F21BFF8371A2 @default.
- Q104456250 P2093 Q104456250-631969AA-301D-4F3D-AE0F-321E63221F7C @default.
- Q104456250 P2093 Q104456250-86DCD4FF-6B9C-48F2-B727-5C4BD9138D85 @default.
- Q104456250 P2093 Q104456250-92AD2D44-0947-4CBA-AC38-CBDE9FAF4A94 @default.
- Q104456250 P2093 Q104456250-95B5FA6B-1AB3-4DB1-89A7-9880DDCC0588 @default.
- Q104456250 P2093 Q104456250-B4C59978-5255-4696-814E-1D78A84A9EFA @default.
- Q104456250 P2093 Q104456250-C8550513-7D17-46E3-B5BB-F5D468815078 @default.
- Q104456250 P304 Q104456250-D4F5B01F-AF1F-43C3-9041-F1146520BD94 @default.
- Q104456250 P31 Q104456250-45F2B094-E2AE-440F-87BA-7E89EED44084 @default.
- Q104456250 P356 Q104456250-AD2B06AD-ADE7-461D-89B3-6B2A686C5514 @default.
- Q104456250 P478 Q104456250-5C1C5434-4005-4061-8162-B26124AA5E98 @default.
- Q104456250 P50 Q104456250-EB2242C0-1C66-4E5A-BE97-16A721D6141F @default.
- Q104456250 P577 Q104456250-46E44831-99EB-49D6-9D81-4B5D2F70EE93 @default.
- Q104456250 P698 Q104456250-0FDFE213-5EEE-4967-8DA4-9146AE66040D @default.
- Q104456250 P356 J.EJMECH.2020.113081 @default.
- Q104456250 P698 33310290 @default.
- Q104456250 P1433 Q3008624 @default.
- Q104456250 P1476 "Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells" @default.
- Q104456250 P2093 "Dana M Zaher" @default.
- Q104456250 P2093 "Hamadeh Tarazi" @default.
- Q104456250 P2093 "Hanan S Anbar" @default.
- Q104456250 P2093 "Mahmoud K Shehata" @default.
- Q104456250 P2093 "Mahta M Khakpour" @default.
- Q104456250 P2093 "Malaka M Zoghbor" @default.
- Q104456250 P2093 "Mohammed I El-Gamal" @default.
- Q104456250 P2093 "Najma A Mohamood" @default.
- Q104456250 P2093 "Nour N Alach" @default.
- Q104456250 P2093 "Randa El-Gamal" @default.
- Q104456250 P2093 "Rawan M Sbenati" @default.
- Q104456250 P2093 "Seyed-Omar Zaraei" @default.
- Q104456250 P304 "113081" @default.
- Q104456250 P31 Q13442814 @default.
- Q104456250 P356 "10.1016/J.EJMECH.2020.113081" @default.
- Q104456250 P478 "210" @default.
- Q104456250 P50 Q47761567 @default.
- Q104456250 P577 "2020-12-04T00:00:00Z" @default.
- Q104456250 P698 "33310290" @default.